Skip to main content

Table 1 Clinical characteristics, immunohistochemical and molecular markers available of patients with grade 1, 2 and 3A

From: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

  N Total Mutated EZH2 in FFPE (n = 36) Unmutated EZH2 p-value
(n = 141) in FFPE (n = 105)
Clinical characteristics at diagnosis, n (%)
 Age at diagnosis, mean (range) 141 62 (15–90) 64 (42–90) 62 (15–89) 0.248
 Sex
  Female 141 82 (58) 23 (64) 59 (56) 0.441
  Male   59 (42) 13 (36) 46 (44)  
 Histology
  Grade 1, 2 131 87 (66) 27 (77) 68 (72) 0.299
  Grade 3A   44 (34) 8 (23) 26 (28)  
 Ki67 124
  Low 55 (44) 16 (29) 39 (71) 0.54
  Intermediate 47 (38) 12 (26) 35 (74) 0.84
  High   22 (18) 5 (23) 17 (77) 0.45
 Stage
  I-II 139 40 (29) 7 (21) 33 (33) 0.204
  III-IV   99 (71) 28 (79) 71 (67)  
 FLIPI risk categories
  Low-Intermediate 124 88 (71) 22 (65) 66 (73) 0.379
  High   36 (29) 12 (35) 24 (27)  
 Bulky mass 140 36 (26) 11 (31) 25 (24) 0.508
 Extranodal 140 34 (24) 8 (22) 26 (25) 0.824
 Bone narrow infiltration 139 47 (34) 13 (37) 34 (33) 0.682
 B-symptoms 140 39 (28) 9 (25) 30 (29) 0.830